Pcp54 - Overview of Methods for Assessing Comparative Evidence for Treatments Evaluated in Early Phase Trials in Oncology

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.09.529

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?

Clinical Cancer Research
Cancer ResearchOncology
2012English

Methods of Blinding in Reports of Randomized Controlled Trials Assessing Pharmacologic Treatments: A Systematic Review

PLoS Medicine
BiochemistryBiotechnologyMolecular BiologyCell BiologyMedicine
2006English

Phase II Cancer Clinical Trials for Biomarker-Guided Treatments

Journal of Biopharmaceutical Statistics
StatisticsProbabilityPharmacology
2017English

A Comparison of Screening Methods in Two Early Phase Oral Leukoplakia Clinical Trials

Oral Diseases
OtorhinolaryngologyDentistry
2012English

Considerations in the Appplication of Novel Statistical Methods for Crossover Adjustment in Trials of Cancer Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Quantitative Imaging Assessment for Clinical Trials in Oncology

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2019English

The Promise of Risk-Based Allocation Trials in Assessing New Treatments.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1996English

Research Participants' High Expectations of Benefit in Early-Phase Oncology Trials: Are We Asking the Right Question?

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Screened Selection Design for Randomised Phase II Oncology Trials: An Example in Chronic Lymphocytic Leukaemia

Trials
MedicinePharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy